Compare Duke Energy Corp (DUK) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Duke Energy Corp vs Tango Therapeutics Inc. — how do they compare? Duke Energy Corp trades at $120.15 (market cap $92.15B), while Tango Therapeutics Inc. trades at $22.23 (market cap $3.75B). The key difference: Duke Energy Corp is far larger — about 24.6× Tango Therapeutics Inc.'s market cap, and Duke Energy Corp pays a 3.67% dividend while Tango Therapeutics Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Duke Energy Corp for 75 Days and Tango Therapeutics Inc. for 0 Days on average.
| DUK | TNGX | |
|---|---|---|
Market Cap | $92.15B | $3.75B |
Volume | 3,498,824 | 9,619,106 |
Sector | Utilities | Health |
52-Week High | $133.46 | $32.90 |
52-Week Low | $113.23 | $7.50 |
Typical Hold Time | 75 Days | 0 Days |
Enterprise Value | $184.66B | $2.77B |
Dividend Yield | 3.67% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Duke Energy (DUK) trades at $119.64, up 1.66% on the day, with a bullish technical signal despite some overbought RSI readings. The company has beaten earnings estimates for three consecutive quarters, with Q3 2026 results pending. Revenue and net income have grown steadily, reaching $32.24B and $4.97B in 2025, respectively, while maintaining strong profitability margins. Recent news highlights dividend declarations and data center growth opportunities.
The outlook for DUK is positive, supported by consistent earnings beats, a solid dividend yield, and strategic positioning in data center contracts. Risks include high debt levels, rising interest rates impacting utility stocks, and execution challenges in capital-intensive projects. Analyst consensus leans hold with a $131.50 price target, suggesting moderate upside from current levels.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Duke Energy Corp
Duke Energy is one of the largest U.S. utilities, with regulated utilities in the Carolinas, Indiana, Florida, Ohio, and Kentucky that deliver electricity to nearly 8 million customers. Its natural gas utilities serve more than 1.5 million customers. Duke operates in three major segments: electric utilities and infrastructure
Read more on DUK →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
